Immunotherapies
To inquire about our available technologies, call our office (813) 745-6828
| Name & Description | Number |
|---|---|
| TIL: Genetically Modified Tumor Infiltrating Lymphocytes and Methods of Producing and Using the Same | 25MA026N |
| TIL: Compositions Of Tumor Infiltrating Lymphocytes (TILs) For Therapy and Related Methods | 25MA023N |
| TIL: Methods For Ex Vivo Enrichment and Expansion of Tumor Reactive T Cells and Related Compositions and Methods | 25MA022N |
| TIL: Methods Of Producing Tumor-Reactive T Cell Composition Using Modulatory Agents | 25MA021N |
| CAR-T: CD112R Based Switch Receptors For CAR-T Therapy | 24MA004N |
| T cell engineering: Reprogramming The CD112-CD112R Axis for Optimized CAR-T | 23MB038N |
| TCR: NYESO1 TCR For T-Cell Therapy and Methods of Use | 23MB030N |
| Vaccine: Survivin mRNA Vaccine | 23MB029N |
| TIL: Method Of Generating TILs from Cerebro Spinal Fluid for Leptomeningeal Disease | 23MB026N |
| BiTE: SSTR-Binding Bi-Specific T-Cell Engaging Molecules | 23MA021N |
| DC Vaccine: Methods Of Treating Leptomeningeal Disease | 23MA018N |
| T cell engineering: Engineered Isoforms of Humanin to Improve T-Cell Therapy | 23MA016 |
| T cell engineering: Bcl11B Sustains Multipotency and Restricts Effector Programs of Intestinal Resident Memory CD8+ T Cells | 23MA009N |
| CAR-T: Anti-TYRP1 CAR-T for Melanoma | 23MA006 |
| DC Vaccine: Enriching Monocyte Derived Dendritic Cells to Create DC Vaccine based Immunotherapy Using L-Fucose | 22MB110N |
| Method: Leveraging L-Fucose-Mediated Signaling to Induce Monocyte-Derived Dendritic Cell Polarization | 22MB108N |
| TIL: Intravesical TIL Therapy in BCG Unresponsive Patients | 22MB107N |
| T cell engineering: Method Of Generating Cells of the T Cell Lineage with Engineering Broadly Reactive Human Notch Ligand | 22MB103N |
| T cell engineering: Bcl-XL Variants for Enhancing Cellular Immunotherapy Function | 22MA088 |
| ACT: Metabolic Reprograming of Adoptively Transferred T Cells to Potentiate Antitumor Response | 22MA082N |
| Method: Use of Anti-Marco Antibody with a Checkpoint Blockade Antibody for the Treatment of Cancer | 22MA080N |
| ACT: Targeting Myeloid-Derived Suppressor Cells (MDSCs) In Bladder Cancer to Enhance Efficacy of Adoptive Cell Therapy (ACT) | 22MA043N |
| TIL: Methods Of Culturing Tumor Infiltrating Lymphocytes | 22MA039N |
| Method: Combination Anti-4-1BB Immunotherapy, Radiotherapy, and B Cell Activation Therapy | 22MA026N |
| TIL: Culture Of Tumor Infiltrating Lymphocytes from Tumor Digest | 22MA011N |
| TCR: KRAS/Tp53 Neoantigen Specific T Cell Receptors | 22MA008N |
| CAR-T: CAR-T Cells with Ablated ER Stress | 21MB097N |
| TILs: aAPCs that expresses an anti-CD3 scFv transmembrane to determine the cytotoxicity of TILs | 21MB083 |
| CAR-T: Downregulating iNOS to Increase CAR-T Killing | 21MB073N |
| CAR-T: Chimeric Antigen Receptors with Mutated Dap10 Costimulatory Domains | 21MB069N |
| CLEC12A: Novel CLEC12A scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy | 21MB064 |
| KRAS: Platform Technology: Dimeric IgA Therapeutic Antibody for Intra-Tumoral Targeting of Mutant KRAS | 21MB061 |
| CAR-T: Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells | 21MA056N |
| Method: DNA Methylation Signatures for Predicting Response to Immunotherapy | 21MA055N |
| CAR-T: CAR-T Cell Therapy for Triple Negative Breast Cancer | 21MA052N |
| CAR-T: Differential Alternative Splicing in Relapsed and Refractory Diffuse Large B-Cell Lymphoma Patients Receiving CAR-T Therapy | 21MA045N |
| Method: Immune Checkpoint Inhibitor and HDAC Inhibitor Combination Therapy Strategy | 21MA042N |
| MDSC: Method of using Oral-L-Fucose to reduce immunosuppressive effect of Myeloid Derived Suppressor Cells (MDSCs) | 21MA028N |
| CAR-T: Engineered Immune Cells with Reduced Sirt6 Expression | 21MA011N |
| Human ITAM Mutated Variants For Better Intracellular Signaling Domains For Gamma-Delta CAR T-Cell Activation | 21MA008N |
| CAR-T: CAR-Ts with Enhanced CD-28 Co-Stimulatory Domains | 21MA005 |
| Mutated Estrogen Receptor Neoantigen Peptide-Pulsed Type I Dendritic Cell (DC1) Vaccine Therapy to Treat Metastatic ER-positive Breast Cancer | 20MB062 - VIDEO |
| Single-domain antibodies (nanobodies) targeting the notch ligand DLL4 to Disrupt the interaction of DLL4 and Notch1 for GVHD | 20MB053N |
| ACT: Inhibition Of Kir2Dl2 for the Enhancement of Adoptive Immunotherapy | 20MB052N |
| Bispecific Gamma Delta CAR-T Cells that Recognize CD33, CD123 and NKG2D Ligands for the Treatment of Acute Myeloid Leukemia | 20MB050N |
| TIL: Novel CD4+ Tumor Infiltrating Lymphocytes for the Treatment of Cancer | 20MB045N |
| Olfactory Receptor Targeting Chimeric Antigen Receptor Expressing T cell (CAR-T) for Solid Tumors | 20MA027 - VIDEO |
| CD33 CD123: Novel Bispecific CD33 CD123 scFv CAR-T Cells for Acute Myeloid Leukemia Immunotherapy | 20MA024 |
| HER-2: Combination Therapy of a HER2-DC1 Dendritic Cell Cancer Vaccine and a Probiotic | 20MA016N |
| TILs: 12 Chemokine Gene Expression Signature to Increase the Efficacy of Manufacturing Tumor Infiltrating Lymphocytes | 20MA013N |
| CAR-T: D99/CLEC12A AND gated Bispecific CAR-T for the Treatment of AML | 20MA009 |
| TCR: Novel T Cell Receptors (TCRs) That React to Neoantigens | 20MA006N |
| PERK, IRE1: Method of Enhancing Immunotherapy Using ER Stress Pathway Inhibitors | 20MA005 - VIDEO |
| CAR-T: HDAC6-Inhibited Human Regulatory T Cells | 20MA004N |
| N-Terminal Mutant PGC-1α Overexpression Enhances Metabolic Fitness Reducing CAR-T Exhaustion while Maintaining Proliferative Capacity | 19MB066T2 |
| CAR-T: Systems And Methods for Producing Efficacious Regulatory CAR T Cells | 19MB060N |
| Fucose Increases Tumor Cell HLA-DRB1 Expression Increasing CD4+ T-cell Activation with Synergistic Tumor Killing Activity with anti-PD1 Checkpoint Inhibitors | 19MB049N |
| Antibodies: Fully Human anti-BDNF Antibodies | 19MB048N |
| Antibodies: Fully Human anti-TSPAN7 Antibodies | 19MB047N |
| DC vaccine: HER3 Peptide Pulsed DC1 Therapy | 19MB043N |
| T-bet: T-bet Transcription Factor Armed CAR-T Cells Maintain Memory Phenotypes and Rescue CD4 Cells Leading to Increased Persistence | 19MA035N |
| EGFR, MUC1: Bispecific CAR-T Cell constructs (chimeric antigen receptors) that Recognize EGFR and MUC1 for the Treatment of Lung Cancer | 19MA033N |
| Bispecific T-Cell Engagers: B Cells Engineered to Express Bispecific T-Cell Engagers Result in Longer Half Lives | 19MA029N |
| NOTCH: Enhancing the Efficacy of Adoptive T-cell Immunotherapy Using Novel Notch Ligands | 19MA026N |
| aAPC: Artificial Antigen-Presenting Cells Expressing NKG2D Ligands for Producing anti-NKG2D CAR-T Cells | 19MA022N |
| NKG2D-Ligand: Enhancing Carcinoma Infiltration by NKG2D-Ligand Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1 | 19MA015NT2 |
| GPC3: Enhancing Carcinoma Infiltration by Anti-GPC3 Targeted CAR-T Cells by Co-Expression of the Chemokine Receptor CX3CR1 | 19MA015N |
| B-RAF: Combination Therapy of TILs and BRAF Inhibitors to Treat BRAF Inhibitor-Resistant Metastatic Melanoma | 19MA007 |
| TILs: Enhancing the anti-tumor immunity of TILs by inhibiting Sirt2 | 18MB078 |
| 18MB072 Method of Using anti-CD277 Antibodies to Treat Cancer | 18MB072 |
| Antibodies: Fully Human anti-LAG3 Antibodies | 18MB062N |
| Antibodies: Fully Human anti-PD1 Antibodies | 18MB061 |
| Brain Mets: Lung Cancer Brain Metastases Targeting CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers | 18MB059 |
| Glioma Stem Cell Targeting CAR-T Cell Constructs with Phage Display Derived Peptide Oligomers | 18MB054 |
| Suicide Switch: CAR-T cells can be Designed to Self-Destruct if Patient shows signs of Toxicity including graft-vs.-host-disease, cytokine release syndrome (CRS), and neurotoxicty | 18MB049N |
| TLR9 Ligand Trap: TLR9-IgG4 Fusion Protein to Neutralize Innate Immune Activation and Chronic Inflammation Contributing to MDS Pathogenesis | 18MB048N |
| Inflammasome: Method of Using Small-molecule Pyrin-domain Targeted NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis | 18MB044N |
| TILs: Method of Using a Demethylating Agent to Enhance STING Expression and TIL Anti-Tumor Activity in Melanoma | 18MA034N |
| TILs: TILs modified with CAR constructs result in CAR-TILs for Cancer Therapy | 18MA033 |
| NKG2D ligands: NKG2D Chimeric Antigen Receptor CAR-T Cells for Acute Myeloid Leukemia Immunotherapy | 18MA023 |
| aAPC: Artificial Antigen-Presenting Cells with Heparin-Binding Domain and Protein L for Producing CAR-T Cells | 18MA019N |
| SSTR2 CAR-T: Somatostatin Receptor 2 Targeting CAR-T Cells for Neuroendocrine Tumors | 18MA013 |
| TILs: The Use of Fucose to Increase TILs for the Immunotherapy of Melanoma | 17MB048 - VIDEO |
| CAR-T: CAR-T Cells with Enhanced 41BB Co-Stimulation | 17MB043 |
| CD99: Novel CD99 scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy | 17MB042 |
| CLEC12A: Novel CLEC12A scFv Targeting CAR-T cells for Acute Myeloid Leukemia Immunotherapy | 17BM041 |
| Inflammasome: Stapled Peptides NLRP3 Inflammasome Inhibitors to Neutralize Pyroptotic Cell Death Contributing to MDS Pathogenesis | 17MB037 |
| CD123: CAR-T Cell Constructs that Recognize CD123 for the Treatment of Acute Myeloid Leukemia | 17MA031 |
| CD33: CAR-T Cell Constructs that Recognize CD33 for the Treatment of Acute Myeloid Leukemia | 17MA030 |
| TILs: Simple and Rapid Method for Culture of TILs from Melanoma Tumor Fragments or Core Needle Biopsies of Solid Tumors | 17MA012 |
| CD3-CD28: Bispecific Antibody for the Generation of CAR-T cells for Cancer Immunotherapy | 17MA007 |